MultiCell Technologies, Inc. is a clinical-stage biopharmaceutical company. The firm develops novel therapeutics and discovery tools that address unmet medical needs for the treatment of neurological disorders, hepatic disease and cancer. Its therapeutic development platform includes several patented techniques used to isolate, characterize and differentiate stem cells from human liver or control the immune response at transcriptional and translational levels through dsRNA-sensing molecules, such as Toll-like receptor, RIG-I-like receptor, and MDA-5 signaling. The company was founded on April 28, 1970 and is headquartered in Woonsocket, RI.
Company profile
Ticker
MCET
Exchange
CEO
W. Gerald Newmin
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Exten Industries Inc, Multicell Technologies Inc.
SEC CIK
Corporate docs
IRS number
521412493
Latest filings (excl ownership)
15-12G
Securities registration termination
13 Jan 17
8-K
Other Events
26 Sep 16
10-Q
2015 Q3
Quarterly report
15 Oct 15
10-Q
2015 Q2
Quarterly report
16 Jul 15
NT 10-Q
Notice of late quarterly filing
16 Jul 15
CT ORDER
Confidential treatment order
22 Jun 15
10-Q
2015 Q1
Quarterly report
14 Apr 15
8-K
Submission of Matters to a Vote of Security Holders
13 Mar 15
8-K
Multicell Immunotherapeutics and Oxis Biotech Sign Antibody-drug Conjugate R&D, Product License and Commercialization Agreement
13 Mar 15
10-K
2014 FY
Annual report
2 Mar 15
Latest ownership filings
SC 13G/A
MultiCell Technologies, Inc.
14 Feb 19
SC 13G
MultiCell Technologies, Inc.
14 Feb 18
SC 13G
MultiCell Technologies, Inc.
14 Feb 17
SC 13G
MultiCell Technologies, Inc.
16 Feb 16
4
Edward Sigmond
30 Jul 15
4
THOMAS PAGE
30 Jul 15
4
W GERALD NEWMIN
30 Jul 15
4
GRANT MILLER
30 Jul 15
4
Stephen Chang
30 Jul 15
SC 13G
MultiCell Technologies, Inc.
17 Feb 15